{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T18:52:49Z","timestamp":1673031169258},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.endinu.2018.09.006","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T20:24:43Z","timestamp":1544819083000},"page":"210-216","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Experiencia tras el cambio de insulina glargina U100 a glargina U300 en pacientes con diabetes tipo 1. Estudio tras un a\u00f1o de tratamiento en vida real"],"prefix":"10.1016","volume":"66","author":[{"given":"Pedro","family":"Pujante Alarc\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"Rodr\u00edguez Escobedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Garc\u00eda Urruzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Manj\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Sanchez Ragnarson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u00edas","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edelmiro L.","family":"Men\u00e9ndez Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endinu.2018.09.006_bib0110","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.endinu.2018.09.006_bib0115","first-page":"17","article-title":"[The development of the incidence of diabetes mellitus I in children 0 to 14 years of age in Malaga (1982-1993)] [art\u00edculo en espa\u00f1ol]","volume":"47","author":"L\u00f3pez Siguero","year":"1997","journal-title":"An Esp Pediatr"},{"key":"10.1016\/j.endinu.2018.09.006_bib0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.endinu.2017.10.013","article-title":"Epidemiology of type 1 diabetes in Asturias: 2002-2011","volume":"65","author":"Mayoral Gonz\u00e1lez","year":"2018","journal-title":"Endocrinol Diabetes Nutr"},{"key":"10.1016\/j.endinu.2018.09.006_bib0125","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.endinu.2018.01.003","article-title":"Incidence of type 1 diabetes mellitus in Navarre stabilized in the last eight years","volume":"65","author":"Forga","year":"2018","journal-title":"Endocrinol Diabetes Nutr"},{"key":"10.1016\/j.endinu.2018.09.006_bib0130","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.09.006_bib0135","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.09.006_bib0140","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/dme.12261","article-title":"Self-reported non-severe hypoglycaemic events in Europe","volume":"31","author":"\u00d6stenson","year":"2014","journal-title":"Diabet Med"},{"key":"10.1016\/j.endinu.2018.09.006_bib0145","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrendo.2014.170","article-title":"Hypoglycaemia in diabetes mellitus: Epidemiology and clinical implications","volume":"10","author":"Frier","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.endinu.2018.09.006_bib0150","doi-asserted-by":"crossref","first-page":"e002875","DOI":"10.1161\/JAHA.115.002875","article-title":"Association between severe hypoglycemia and cardiovascular disease risk in Japanese patients with type 2 diabetes","volume":"5","author":"Goto","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.endinu.2018.09.006_bib0155","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2337\/dc12-0916","article-title":"Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: A nationwide population-based study","volume":"36","author":"Hsu","year":"2013","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.endinu.2018.09.006_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.17.S2.1","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan","volume":"17","author":"Handelsman","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.endinu.2018.09.006_bib0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/dom.12416","article-title":"Low within- and between-day variability in exposure to new insulin glargine 300 U\/ml","volume":"17","author":"Becker","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endinu.2018.09.006_bib0170","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/dc16-0684","article-title":"Comparison of insulin glargine 300 units\/mL and 100 units\/mL in adults with type 1 diabetes: Continuous glucose monitoring profiles and variability using morning or evening injections","volume":"40","author":"Bergenstal","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.09.006_bib0175","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","article-title":"Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia","volume":"28","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.09.006_bib0180","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/dom.13199","article-title":"Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units\/mL vs other basal insulins in patients with type 2 diabetes using basal insulin","volume":"20","author":"Zhou","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endinu.2018.09.006_bib0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/dom.13048","article-title":"Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U\/mL versus glargine 100 U\/mL in people with type 1 diabetes (EDITION 4)","volume":"20","author":"Home","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endinu.2018.09.006_bib0190","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.diabres.2017.03.036","article-title":"Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study","volume":"129","author":"Gradiser","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.endinu.2018.09.006_bib0195","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc15-0249","article-title":"New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 1 diabetes: A randomized, phase 3a open-label clinical trial (EDITION 4)","volume":"38","author":"Home","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endinu.2018.09.006_bib0200","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/dom.12619","article-title":"New insulin glargine 300 U\/ml versus glargine 100 U\/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: Glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)","volume":"18","author":"Matsuhisa","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endinu.2018.09.006_bib0205","doi-asserted-by":"crossref","first-page":"e009421","DOI":"10.1136\/bmjopen-2015-009421","article-title":"Safety and efficacy of insulin glargine 300 u\/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: A network meta-analysis","volume":"6","author":"Freemantle","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.endinu.2018.09.006_bib0210","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/DMSO.S131358","article-title":"Insulin glargine 300 U\/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus","volume":"10","author":"Lau","year":"2017","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016418302453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016418302453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:01:09Z","timestamp":1554163269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530016418302453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2530016418302453"],"URL":"https:\/\/doi.org\/10.1016\/j.endinu.2018.09.006","relation":{},"ISSN":["2530-0164"],"issn-type":[{"value":"2530-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experiencia tras el cambio de insulina glargina U100 a glargina U300 en pacientes con diabetes tipo 1. Estudio tras un a\u00f1o de tratamiento en vida real","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2018.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SEEN y SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}